29

Jul2016

SAVE THE DATE

PDCI’s PMPRB Guidelines Modernization Webinar Session On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”.  The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range ... Read More

21

Jul2016

PMPRB 2015 Annual Report

Correction to the below TargetPharma (“PMPRB 2015 Annual Report”) sent out on July 21, 2016. The PMPRB report tabled in Parliament was their report with respect to the Access to Information Act and to the Privacy Act and not the anticipated “2015 PMPRB Annual Report” which was not tabled and now ... Read More

12

Jul2016

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016: 33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016: Abilify (aripiprazole): used for the treatment of schizophrenia and related ... Read More

04

Jul2016

PMPRB Guideline Modernization – PDCI to hold Industry Information Sessions in August / September

On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”.  The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range of issues that will inform ... Read More

27

Jun2016

PMPRB – Discussion Paper Released – Board Down to 2 Board Members as of June 27 – 2015 Annual Report Board Delayed

Discussion Paper.  On Friday June 24, the PMPRB released a long delayed discussion paper covering a wide range of issues that go to the core of the PMPRB’s price regulation mandate.  The PMPRB will be seeking input from stakeholders over the Summer/Fall of 2016 and will hold public policy hearings ... Read More

20

Jun2016

PDCI Releases NEW Report on pCPA Best Practices, Trends and Outlook

In February 2015, PDCI Market Access (PDCI) released a report entitled pCPA Negotiation Guidelines. That report, which was a collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and PDCI, was meant to provide guidance to manufacturers on pCPA’s expectations surrounding negotiations. Although the pCPA Negotiation Guidelines report outlined how manufacturers should ... Read More

03

Jun2016

BC PharmaCare Upcoming Modernization of the Reference Drug Program

The British Columbia PharmaCare (BC PharmaCare) is modernizing the Reference Drug Program (RDP). Effective immediately, transitional coverage is in place to allow affected patients to switch drugs, if needed, to retain full PharmaCare coverage. During transition, PharmaCare will cover all Modernized RDP fully covered drugs and all original RDP fully ... Read More

01

Jun2016

RAMQ: June 2016 Update for the List of Medications

The Régie de l’assurance maladie du Québec (RAMQ) is scheduled to release its June update of the List of Medications on June 13, 2016 which will come into effect on June 15, 2016. For more information and to see the list update schedule, please visit the RAMQ website.

26

May2016

CADTH CDR and pCODR Engagement with the pCPA

Effective immediately, CADTH will be formally engaging with the pan-Canadian Pharmaceutical Alliance (pCPA) and will be including the pCPA office in the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) processes. This will provide an opportunity for the pCPA office to receive relevant information on drugs reviewed ... Read More

25

May2016

Nova Scotia Pharmacare Funds INFLECTRA™ (infliximab)

Effective June 1, 2016, the Nova Scotia Pharmacare will begin funding INFLECTRA™ (infliximab) as an exception status benefit. For infliximab-naïve patients whose infliximab therapy is initiated after June 1, 2016, Inflectra will be the product approved for the following indications: Rheumatoid Arthritis Ankylosing Spondylitis Psoriasis Criteria Updates – Rheumatoid Arthritis The Atlantic ... Read More